|
|
| (118 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | + | {{gohome}} |
| | + | {{ft|P}} |
| | + | '''CHERRYPICKING STUDIES IS NOT SCIENCE |
| | + | {{qt|Reviews on covid drug development}} |
| | | | |
| | | | |
| − | '''reviews candidate compounds covid19''' | + | *'''[[scouting ideas]]''' |
| − | {{tp|p=32226821|t=2020. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases |pdf=|usr=}}
| + | |
| − | {{tp|p=32292689|t=ä. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods |pdf=|usr=}}
| + | |
| − | {{tp|p=32318328|t=ä. D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32152082|t=2020. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus |pdf=|usr=}}
| + | |
| − | {{tp|p=32232214|t=2020. Potential Treatments for COVID-19; a Narrative Literature Review |pdf=|usr=}}
| + | |
| − | {{tp|p=32134278|t=2020. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32375268|t=2020. Coronavirus Pandemic-Therapy and Vaccines |pdf=|usr=}}
| + | |
| − | {{tp|p=31996494|t=2020. Drug treatment options for the 2019-new coronavirus (2019-nCoV) |pdf=|usr=}}
| + | |
| − | {{tp|p=32334062|t=ä. Current status of potential therapeutic candidates for the COVID-19 crisis |pdf=|usr=}}
| + | |
| | | | |
| | + | *'''[[PHA Biologicals]]''' |
| | | | |
| − | '''Macrolide antibiotics''' | + | *'''[[PHA conventional pharmacology]]''' |
| − | {{tp|p=32249257|t=2020. Macrolide treatment for COVID-19: Will this be the way forward?|pdf=|usr=}}
| + | |
| | | | |
| − | '''Oleoylethanolamide''' | + | *'''[[PHA retargeted compounds]]''' |
| − | {{tp|p=32327293|t=ä. Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19 |pdf=|usr=}}
| + | |
| | | | |
| − | '''Metronidazole''' retarget | + | *'''[[PHA antivirals by mechanism]]''' |
| − | {{tp|p=32259129|t=2020. Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen |pdf=|usr=}}
| + | |
| | | | |
| − | '''Glutathione GSH''' antioxidant | + | *'''[[PHA pharmacophore by screened target]]''' |
| − | *[https://nypost.com/2020/05/09/new-york-mom-with-coronavirus-saved-by-medical-student-son/ found in a forrest gump mode]
| + | |
| − | *[https://www.sciencedirect.com/science/article/pii/S2213007120301350 Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases]
| + | |
| | | | |
| − | '''Chlorpromazine''' retarget | + | *'''[[PHA ImmunoNutrients]] |
| − | *[https://www.biorxiv.org/content/10.1101/2020.05.05.079608v1 paper]
| + | |
| | | | |
| − | '''Zinc''' add-on | + | *'''[[PHA compl altern natural]]''' |
| − | *[https://www.sciencedirect.com/science/article/pii/S0306987720306435 call for trial]
| + | |
| | | | |
| − | '''Selenium''' | + | *'''[[PHA within indications compounds]]''' |
| − | {{tp|p=32342979|t=ä. Association between regional selenium status and reported outcome of COVID-19 cases in China |pdf=|usr=}}
| + | |
| | | | |
| − | '''Remdesivir''' retarget | + | *'''[[PHA Serum products]]''' |
| − | *[https://gab.com/Remnant601/posts/104122987152232660 one hospital on...]
| + | |
| − | {{tp|p=32283108|t=ä. Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites |pdf=|usr=}}
| + | |
| | | | |
| − | '''Lauric acid''' nat. compd. | + | *'''[[PHA Vaccination]]''' |
| − | *[https://www.icp.org.ph/2020/01/the-potential-of-coconut-oil-and-its-derivatives-as-effective-and-safe-antiviral-agents-against-the-novel-coronavirus-ncov-2019/ call for trial]
| + | |
| | | | |
| − | '''Nicotine''' nat. toxin
| + | PHA related options: |
| − | *[https://www.usatoday.com/story/news/factcheck/2020/05/03/covid-19-fact-check-caution-urged-study-virus-smoking/3055378001/ france]
| + | |
| | | | |
| − | '''Niclosamide'''
| + | *[[Radiation therapy]] |
| − | {{tp|p=32125140|t=ä. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential |pdf=|usr=}}
| + | *[[Phototherapy]] |
| | + | *[[Electric fields]] |
| | + | *[[Treatment other concepts]] |
| | | | |
| − | '''Microbiome as target'''
| |
| − | {{tp|p=32356654|t=ä. Considering the Effects of Microbiome and Diet on SARS-CoV-2 Infection: Nanotechnology Roles |pdf=|usr=}}
| |
| | | | |
| − | '''ACE2 as target'''
| + | A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea. |
| − | {{tp|p=32286790|t=ä. Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2 |pdf=|usr=}}
| + | This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world |
| | + | vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents. |
| | + | Paper is (not yet in PubMed) : |
| | | | |
| − | '''Garlic extracts''' | + | *'''[https://www.sciencedirect.com/science/article/pii/S1097276520305499?via%3Dihub Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication at Mol Cell 2020/08/11]''' |
| − | {{tp|p=32363255|t=ä. Investigation into SARS-CoV-2 Resistance of Compounds in Garlic Essential Oil |pdf=|usr=}}
| + | credentials to [https://web.de/magazine/news/coronavirus/coronavirus-blockade-zellulaerer-kommunikation-forscher-stoppen-vermehrung-sars-cov-2-35045170 Marinus Brandl] who told us about it today. |
| | + | based on e.g. |
| | | | |
| − | '''Dipyridamole''' retarget
| + | {{ttp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |pdf=|usr=}} |
| − | {{tp|p=32318327|t=ä. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19 |pdf=|usr=}} | + | |
| | | | |
| − | '''stem cells'''
| + | ======================================================================================= |
| − | {{tp|p=32257554|t=2020. Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32257537|t=2020. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia |pdf=|usr=}}
| + | |
| | | | |
| − | '''Ivermectin'''
| + | COVID19 is now a CURABLE disease !!! |
| − | {{tp|p=32330482|t=ä. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors responses |pdf=|usr=}}
| + | |
| | | | |
| − | '''Various Leads'''
| + | ======================================================================================= |
| − | *[https://theconversation.com/we-found-and-tested-47-old-drugs-that-might-treat-the-coronavirus-results-show-promising-leads-and-a-whole-new-way-to-fight-covid-19-136789 9 retargeted: ternatin4, zotatifin, plitidepsin; haloperidol, melperone, clemastine, cloperastine, pb28, progesterone]
| + | |
| − | *[https://doi.org/10.1038/s41586-020-2286-9 paper in nature]
| + | |
| − | {{tp|p=32251767|t=2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | '''Interferons'''
| + | |
| − | {{tp|p=32275914|t=2020. Type 1 interferons as a potential treatment against COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32360182|t=2020. Antiviral activities of type I interferons to SARS-CoV-2 infection |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | '''Therapeutic antibodies (virus-targeted)'''
| + | |
| − | *[https://www.foxnews.com/science/man-made-antibody-neutralizes-coronavirus-first-time anti covid mab]
| + | |
| − | *[https://www.telegraaf.nl/nieuws/750205601/nederlands-antilichaam-47-d11-blokkeert-infectie-coronavirus acmab 47d11]
| + | |
| − | | + | |
| − | '''Therapeutic antibodies and biologicals (cytokine/sugnal transduction)'''
| + | |
| − | {{tp|p=32247642|t=ä. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report |pdf=|usr=}}
| + | |
| − | {{tp|p=32241793|t=2020. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies |pdf=|usr=}}
| + | |
| − | {{tp|p=32243501|t=2020. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | '''Other antirheumatic compounds'''
| + | |
| − | | + | |
| − | ''Hydroxy-Chloroquine''
| + | |
| − | | + | |
| − | *check retina status; monitor rhythm known toxicity
| + | |
| − | *[https://justthenews.com/politics-policy/coronavirus/doctors-find-hydroxychloroquin-success-rate-91-urge-arizona-maybe-make 91% benefit]
| + | |
| − | *[https://www.themoscowtimes.com/2020/04/17/russia-approves-unproven-malaria-drug-to-treat-coronavirus-a70025 approval russia]
| + | |
| − | *[https://m.timesofindia.com/business/india-business/covid-19-68-new-companies-get-fdca-permit-to-make-hcq/amp_articleshow/75566317.cms scale up production]
| + | |
| − | *[https://www.medrxiv.org/content/10.1101/2020.04.26.20081059v1.full.pdf+html on safety, trial]
| + | |
| − | *[https://www.nejm.org/doi/full/10.1056/NEJMoa2012410?query=C19&cid=DM91569_NEJM_Registered_Users_and_InActive&bid=193180241 Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19] ''substance is useless.''
| + | |
| − | {{tp|p=32232419|t=ä. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know |pdf=|usr=}}
| + | |
| − | {{tp|p=32227189|t=ä. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32147496|t=2020. Of chloroquine and COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32074550|t=2020. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies |pdf=|usr=}}
| + | |
| − | {{tp|p=32321905|t=2020. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database |pdf=|usr=}}
| + | |
| − | {{tp|p=32281583|t=2020. Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32265182|t=2020. Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | '''Chemoprevention Covid19'''
| + | |
| − | | + | |
| − | '''Antiviral agents Covid19'''
| + | |
| − | | + | |
| − | '''Lung regeneration and repair after Covid19'''
| + | |
| − | | + | |
| − | '''resilience enhancement'''
| + | |
| − | {{tp|p=32229705|t=2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections |pdf=|usr=}}
| + | |
| − | {{tp|p=32311498|t=ä. The impact of nutrition on COVID-19 susceptibility and long-term consequences |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | '''psychoneuroimmunology'''
| + | |
| − | {{tp|p=32234338|t=ä. Using psychoneuroimmunity against COVID-19 |pdf=|usr=}}
| + | |
| − | | + | |
| − | '''cannabinoids'''
| + | |
| − | {{tp|p=32360437|t=ä. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?|pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | '''Complementary & Traditional chinese medicine & Ethnopharm'''
| + | |
| − | {{tp|p=32245701|t=ä. Is traditional Chinese medicine useful in the treatment of COVID-19?|pdf=|usr=}}
| + | |
| − | {{tp|p=32233641|t=2020. Network pharmacology-based analysis of the role of traditional Chinese herbal medicines in the treatment of COVID-19 |pdf=|usr=}}
| + | |
| − | *[https://www.aa.com.tr/en/africa/madagascar-slams-who-for-not-endorsing-its-herbal-cure/1836905 madagascar herbs]
| + | |
| − | {{tp|p=32229706|t=2020. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?|pdf=|usr=}}
| + | |
| − | {{tp|p=32037389|t=2020. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment |pdf=|usr=}}
| + | |
| − | {{tp|p=32334064|t=ä. Ayurveda and COVID-19: where psychoneuroimmunology and the meaning response meet |pdf=|usr=}}
| + | |
| − | | + | |
| − | '''Exercise'''
| + | |
| − | {{tp|p=32311497|t=ä. The immunological case for staying active during the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | | + | |
| − | '''Topical agents''' opening up the world of nano...
| + | |
| − | *[https://www.dailymail.co.uk/sciencetech/article-8315269/Commercial-mouthwash-prevent-COVID-19-transmission-scientists-say.html on mouth rinses]
| + | |
| − | | + | |
| − | '''Anticoagulants'''
| + | |
| − | *[[Anticoagulant in covid19]]
| + | |
| − | | + | |
| − | '''Vaccination Covid19'''
| + | |
| − | {{tp|p=32105090|t=2020. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic |pdf=|usr=}}
| + | |
| − | *[https://patch.com/massachusetts/cambridge/ma-company-takes-critical-step-toward-covid-19-vaccine mrna-1273, moderna]
| + | |
